Windtree Therapeutics (WINT) Competitors $0.07 -0.01 (-8.75%) As of 09/5/2025 03:43 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock WINT vs. GRTX, SCNI, ASLN, VCNX, EVFM, ZVSA, NMTR, PTPI, TNFA, and BPTHShould you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Galera Therapeutics (GRTX), Scinai Immunotherapeutics (SCNI), ASLAN Pharmaceuticals (ASLN), Vaccinex (VCNX), Evofem Biosciences (EVFM), ZyVersa Therapeutics (ZVSA), 9 Meters Biopharma (NMTR), Petros Pharmaceuticals (PTPI), TNF Pharmaceuticals (TNFA), and Bio-Path (BPTH). These companies are all part of the "pharmaceutical products" industry. Windtree Therapeutics vs. Its Competitors Galera Therapeutics Scinai Immunotherapeutics ASLAN Pharmaceuticals Vaccinex Evofem Biosciences ZyVersa Therapeutics 9 Meters Biopharma Petros Pharmaceuticals TNF Pharmaceuticals Bio-Path Windtree Therapeutics (NASDAQ:WINT) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment. Which has higher valuation and earnings, WINT or GRTX? Galera Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWindtree TherapeuticsN/AN/A-$1.79M-$823.470.00Galera TherapeuticsN/AN/A-$59.08M-$0.19-0.09 Does the media refer more to WINT or GRTX? In the previous week, Windtree Therapeutics had 4 more articles in the media than Galera Therapeutics. MarketBeat recorded 4 mentions for Windtree Therapeutics and 0 mentions for Galera Therapeutics. Windtree Therapeutics' average media sentiment score of 1.29 beat Galera Therapeutics' score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Windtree Therapeutics Positive Galera Therapeutics Neutral Is WINT or GRTX more profitable? Galera Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Windtree TherapeuticsN/A -207.34% -50.19% Galera Therapeutics N/A N/A -99.34% Do analysts recommend WINT or GRTX? Windtree Therapeutics currently has a consensus price target of $350.00, indicating a potential upside of 479,352.05%. Given Windtree Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Windtree Therapeutics is more favorable than Galera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in WINT or GRTX? 29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, WINT or GRTX? Windtree Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. SummaryWindtree Therapeutics beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks. Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WINT vs. The Competition Export to ExcelMetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.14M$3.13B$5.81B$9.92BDividend YieldN/A2.28%6.71%4.52%P/E Ratio0.0021.1076.0226.12Price / SalesN/A283.48477.0086.71Price / CashN/A44.9736.9659.04Price / Book0.079.8711.456.09Net Income-$1.79M-$53.42M$3.29B$266.51M7 Day PerformanceN/A2.93%1.22%0.45%1 Month PerformanceN/A9.85%7.89%4.58%1 Year PerformanceN/A15.74%62.81%26.06% Windtree Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WINTWindtree Therapeutics2.8336 of 5 stars$0.07-8.8%$350.00+479,352.1%-100.0%$2.14MN/A0.0030Positive NewsShort Interest ↓GRTXGalera TherapeuticsN/A$0.02-2.7%N/A-75.7%$1.66MN/A-0.0630Gap DownSCNIScinai Immunotherapeutics0.7349 of 5 stars$1.54-3.8%N/A-57.7%$1.60M$660K-0.1620ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330VCNXVaccinex0.4243 of 5 stars$0.46-54.0%N/A-90.2%$1.20M$388K-0.0140Negative NewsShort Interest ↑Gap UpEVFMEvofem Biosciences0.7604 of 5 stars$0.01+7.7%N/A+1.0%$1.16M$11.39M-0.02120Short Interest ↑Gap UpZVSAZyVersa Therapeutics0.9527 of 5 stars$0.13-2.8%N/A-95.0%$1.07MN/A0.002Gap DownNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020PTPIPetros Pharmaceuticals0.7191 of 5 stars$0.03+12.7%N/A-99.6%$966K$5.11M-0.0120Gap DownTNFATNF PharmaceuticalsN/A$0.07+9.6%N/AN/A$890KN/A-0.036News CoverageAnalyst UpgradeStock SplitGap UpBPTHBio-Path0.5016 of 5 stars$0.10-16.7%N/A-87.5%$831KN/A0.0010Short Interest ↑Gap Up Related Companies and Tools Related Companies GRTX Competitors SCNI Competitors ASLN Competitors VCNX Competitors EVFM Competitors ZVSA Competitors NMTR Competitors PTPI Competitors TNFA Competitors BPTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WINT) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free WINT Stock Alerts